Drs Kathy Miller and Sunil Badve discuss how HER2 testing has evolved over time as the need for that clinical testing has shifted, including assay limits, biology, and clinical impact.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002986. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

Standardized Pathology Report for HER2 Testing in Compliance With 2023 ASCO/CAP Updates and 2023 ESMO Consensus Statements on HER2-Low Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37770765/

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update https://pubmed.ncbi.nlm.nih.gov/37284804/

Human Breast Cancer: Correlation of Relapse and Survival With Amplification of the HER-2/neu Oncogene https://pubmed.ncbi.nlm.nih.gov/3798106/

Inhibition of Tumor Growth by a Monoclonal Antibody Reactive With an Oncogene-Encoded Tumor Antigen https://pubmed.ncbi.nlm.nih.gov/3466178/

HercepTest https://www.accessdata.fda.gov/cdrh_docs/pdf/P980018S010b.pdf

Effective Extracellular Payload Release and Immunomodulatory Interactions Govern the Therapeutic Effect of Trastuzumab Deruxtecan (T-DXd) https://pubmed.ncbi.nlm.nih.gov/40175391/

Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients With HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience https://pubmed.ncbi.nlm.nih.gov/35008143/

Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies https://pubmed.ncbi.nlm.nih.gov/38471052/

Evidence Accumulates Against Sequencing Topo1-ADCs in HER2-Low Metastatic Breast Cancers: Results From International, Retrospective, Real-world ADC-Low-Europe Cohort https://sabcs.multilearning.com/sabcs/2025/eposters/4192135/francois.poumeaud.evidence.accumulates.against.sequencing.topo1-adcs.in.html

Reversal of Tamoxifen Resistant Breast Cancer by Low Dose Estrogen Therapy https://pubmed.ncbi.nlm.nih.gov/15860267/